Vyne Therapeutics Company Insiders

VYNE Stock  USD 2.96  0.01  0.34%   
Vyne Therapeutics' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Vyne Therapeutics suggests that all insiders are extremely bullish. Vyne Therapeutics employs about 10 people. The company is managed by 11 executives with a total tenure of roughly 24 years, averaging almost 2.0 years of service per executive, having 0.91 employees per reported executive.

Vyne Therapeutics' Insider Buying Vs Selling

100

 
Selling
 
Buying

Latest Trades

2023-11-15Patrick G LeporeAcquired 13000 @ 3.91View
2023-03-20Patrick G LeporeAcquired 20000 @ 2.48View
2021-11-30Patrick G LeporeAcquired 694 @ 18.36View
Monitoring Vyne Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.

Vyne Therapeutics' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Vyne Therapeutics' future performance. Based on our forecasts, it is anticipated that Vyne will maintain a workforce of about 30 employees by December 2024.
 
Covid

Vyne Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.3454) % which means that it has lost $0.3454 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6047) %, meaning that it created substantial loss on money invested by shareholders. Vyne Therapeutics' management efficiency ratios could be used to measure how well Vyne Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 30, 2024, Return On Tangible Assets is expected to decline to -0.31. In addition to that, Return On Capital Employed is expected to decline to -0.34. At present, Vyne Therapeutics' Net Tangible Assets are projected to decrease significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 2.9 M, whereas Total Current Assets are forecasted to decline to about 78.4 M.
The current year's Common Stock Shares Outstanding is expected to grow to about 10.8 M, whereas Net Loss is forecasted to decline to (21.9 M).

Vyne Therapeutics Workforce Comparison

Vyne Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,457. Vyne Therapeutics maintains roughly 10.0 in number of employees contributing less than 1% to equities under Health Care industry.

Vyne Therapeutics Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vyne Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vyne Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Vyne Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-06-01
0.25
1
4
 4,429 
 1,416 
2024-03-01
3.5
14
4
 965,000 
 1,415 
2023-12-01
2.5
15
6
 940,284 
 7,804,422 
2023-06-01
0.5
2
4
 6,430 
 1,380 
2023-03-01
0.5
2
4
 30,000 
 4,076 
2022-12-01
0.25
1
4
 34,705 
 14,572 
2022-09-01
2.25
9
4
 184,500 
 14,568 
2022-06-01
0.5
2
4
 24,397 
 14,569 
2022-03-01
2.25
9
4
 1,149,605 
 31,058 
2021-12-01
0.75
3
4
 21,392 
 9,827 
2021-09-01
2.1429
15
7
 1,141,282 
 855,163 
2021-06-01
0.2727
3
11
 16,458 
 1,077,432 
2021-03-01
2.4
12
5
 5,128,784 
 13,361 
2020-12-01
1.0
4
4
 72,561 
 15,397 
2020-09-01
1.8
9
5
 347,500 
 86,980 
2020-06-01
3.125
25
8
 6,621,675 
 32,897 
2020-03-01
4.6154
60
13
 2,850,666 
 8,609 
2019-12-01
0.6429
9
14
 850,890 
 980,045 
2019-03-01
1.0
1
1
 33,355 
 25,000 
2018-06-01
1.5
3
2
 340,850 
 180,092 
2018-03-01
0.8438
27
32
 13,037,714 
 15,385,071 

Vyne Therapeutics Notable Stakeholders

A Vyne Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Vyne Therapeutics often face trade-offs trying to please all of them. Vyne Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Vyne Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
David DomzalskiPresident CEOProfile
Tyler CPACFO TreasurerProfile
Russell DPhilVP DevelProfile
Iain StuartChief OfficerProfile
MS MDConsultantProfile
Subhashis MDSenior DevelopmentProfile
David SchuzVP PropertyProfile
Faad MDConsultantProfile
Tyler ZerondaPrincipal CFOProfile
MD FAADConsultantProfile
Mutya JDChief CounselProfile

About Vyne Therapeutics Management Performance

The success or failure of an entity such as Vyne Therapeutics often depends on how effective the management is. Vyne Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Vyne management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Vyne management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.29)(0.31)
Return On Capital Employed(0.32)(0.34)
Return On Assets(0.29)(0.31)
Return On Equity(0.32)(0.34)
Please note, the presentation of Vyne Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Vyne Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Vyne Therapeutics' management manipulating its earnings.

Vyne Therapeutics Workforce Analysis

Traditionally, organizations such as Vyne Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Vyne Therapeutics within its industry.

Vyne Therapeutics Manpower Efficiency

Return on Vyne Therapeutics Manpower

Revenue Per Employee42.4K
Revenue Per Executive38.5K
Net Loss Per Employee2.8M
Net Loss Per Executive2.6M
Working Capital Per Employee8.8M
Working Capital Per Executive8M

Complementary Tools for Vyne Stock analysis

When running Vyne Therapeutics' price analysis, check to measure Vyne Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vyne Therapeutics is operating at the current time. Most of Vyne Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vyne Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vyne Therapeutics' price. Additionally, you may evaluate how the addition of Vyne Therapeutics to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges